DOCSLIB.ORG

A Ferrous-Triapine Complex Mediates Formation of Reactive Oxygen Species That Inactivate Human Ribonucleotide Reductase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Ferrous-Triapine Complex Mediates Formation of Reactive Oxygen Species That Inactivate Human Ribonucleotide Reductase 586 A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase Jimin Shao,1,2 Bingsen Zhou,1 Angel J. Di Bilio,3 cytotoxicity assays. These results indicate that Triapine- Lijun Zhu,1,2 Tieli Wang,1 Christina Qi,1 induced inhibition of ribonucleotide reductase is caused by Jennifer Shih,1 and Yun Yen1 ROS. We suggest that ROS may ultimately be responsible for the pharmacologic effects of Triapine in vivo. [Mol 1Department of Medical Oncology and Therapeutic Research, Cancer Ther 2006;5(3):586–92] City of Hope National Medical Center, Duarte, California; 2Department of Basic Medical Sciences, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of Introduction 3 China; Department of Chemistry, California Institute of Ribonucleotide reductases catalyze the reduction of Technology, Pasadena, California ribonucleotides to deoxyribonucleotides, which are re- quired for DNA replication and repair (1, 2). Human Abstract ribonucleotide reductase is a protein tetramer featuring Ribonucleotide reductase plays a central role in cell two identical large (hRRM1) and two identical small proliferation by supplying deoxyribonucleotide precursors (hRRM2 or p53R2) subunits. hRRM1 harbors the sub- for DNA synthesis and repair. The holoenzyme is a protein strate-catalytic and allosteric regulation sites. The small tetramer that features two large (hRRM1) and two small subunit contains an oxygen-linked diferric cluster and a (hRRM2 or p53R2) subunits. The small subunit contains a stable tyrosyl radical that are needed for function (Fig. 1A; refs. 1–4). p53R2 is a newly identified p53-inducible di-iron cluster/tyrosyl radical cofactor that is essential for f enzyme activity. Triapine (3-aminopyridine-2-carboxalde- protein that has 80% sequence homology with hRRM2 hyde thiosemicarbazone, 3-AP) is a new, potent ribonu- (5, 6). It has been suggested that hRRM2/hRRM1 supplies cleotide reductase inhibitor currently in phase II clinical deoxynucleotide triphosphates for DNA replication in a trials for cancer chemotherapy. Ferric chloride readily cell cycle–dependent manner, whereas p53R2/hRRM1 reacts with Triapine to form an Fe(III)-(3-AP) complex, supplies deoxynucleotide triphosphates for DNA repair which is reduced to Fe(II)-(3-AP) by DTT. Spin-trapping in a p53-dependent manner (7–10). The discovery of experiments with 5,5-dimethyl-1-pyrroline-N-oxide prove p53R2 has created much interest because of its possible role in tumorigenesis and cancer treatment (4–8). In- that Fe(II)-(3-AP) reduces O2 to give oxygen reactive species (ROS). In vitro activity assays show that Fe(II)-(3- creased ribonucleotide reductase activity is observed in AP) is a much more potent inhibitor of hRRM2/hRRM1 and tumor formation and metastasis (11–13). Inactivation of p53R2/hRRM1 than Triapine. Electron paramagnetic res- ribonucleotide reductase stops DNA synthesis, which onance measurements on frozen solutions of hRRM2 and inhibits cell proliferation. Thus, the enzyme has long been p53R2 show that their tyrosyl radicals are completely considered an excellent target for cancer chemotherapy. quenched by incubation with Fe(II)-(3-AP). However, the Strategies for inhibiting ribonucleotide reductase include enzyme activity is maintained in protein samples supple- quenching the tyrosyl radical of the small subunit, use of mented with catalase alone or in combination with nucleoside analogues to inhibit the large subunit, pertur- superoxide dismutase. Furthermore, catalase alone or in bation of interactions between subunits, and suppression combination with superoxide dismutase markedly of gene expression (13–15). decreases the antiproliferative effect of Triapine in Triapine (3-aminopyridine-2-carboxaldehyde thiosemi- carbazone, 3-AP) is a new, potent inhibitor of ribonucleo- tide reductase currently in phase II clinical trials for cancer chemotherapy (Fig. 1B; refs. 16–19). Triapine belongs to a class of heterocyclic carboxaldehyde thiosemicarbazones Received 9/22/05; revised 12/6/05; accepted 1/10/06. (HCT) that are efficient iron chelators (16, 17). Ribonucleo- Grant support: National Cancer Institute grant R01 CA72767 and Sino tide reductases are the primary cellular target of Triapine. America Cancer Foundation. The presence of iron is required for effective enzyme The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked inhibition and cytotoxicity by this compound (3, 16, 17). advertisement in accordance with 18 U.S.C. Section 1734 solely to The well-known antitumor drug hydroxyurea is the only indicate this fact. prescribed ribonucleotide reductase inhibitor that targets Requests for reprints: Yun Yen, Department of Medical Oncology and the small subunits (4, 13). Triapine is a 100- to 1,000-fold Therapeutic Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010. Phone: 626-359-8111, ext. 62307; more potent inhibitor of both ribonucleotide reductase and Fax: 626-301-8233. E-mail: [email protected] tumor cell growth than hydroxyurea. The compound is fully Copyright C 2006 American Association for Cancer Research. active against hydroxyurea-resistant tumors and increases doi:10.1158/1535-7163.MCT-05-0384 the effectiveness of other DNA-damaging and cytotoxic Mol Cancer Ther 2006;5(3). March 2006 Downloaded from mct.aacrjournals.org on October 2, 2021. © 2006 American Association for Cancer Research. Molecular Cancer Therapeutics 587 cytotoxicity. Our data strongly suggest that ROS are ultimately responsible for the pharmacologic effects of Triapine. A better understanding of the mechanisms of action of Triapine could result in clinical applications and help design novel ribonucleotide reductase inhibitors for cancer chemotherapy. Materials and Methods Materials Triapine was a gift from Vion Pharmaceuticals, Inc. (New Haven, CT). DMSO, ferric chloride, DTT, superoxide dismutase (SOD, from bovine liver, 2,880 units/mg), catalase (from human erythrocytes, 59,500 units/mg), 5, 5-dimethyl-1-pyrroline-N-oxide (DMPO), and diethylene- triaminepentaacetic acid were supplied by Sigma (St. Louis, MO). Hydrogen peroxide was purchased from Mallinck- rodt Baker, Inc. (Paris, KY). Solutions of Triapine were prepared in neat DMSO and diluted with 50 mmol/L Tris-HCl buffer (pH 7.2) contain- ing 100 mmol/L KCl. Fe(III)-(3-AP) formed readily by mixing Triapine with ferric chloride in a 2:1 ligand to metal ratio at room temperature. Fe(II)-(3-AP) was generated by reduction of Fe(III)-(3-AP) with DTT (20, 21). Triapine is insoluble in water but soluble in aqueous DMSO. Thus, all solutions of Triapine and its iron complexes contained DMSO. UV-Visible Spectrum Measurements UV-visible spectra were measured with a Bio-Rad Figure 1. A, structural model for the di-iron cluster/tyrosyl radical SmartSpec 3000 Spectrophotometer. The samples of Tri- cofactor of p53R2. Protein atoms that bind to the irons are drawn in ‘‘ball- apine and its iron complexes were prepared as described 138 and-stick’’ style. Radical-harboring Tyr (176). The residue numbers in above. Three doses of Triapine (500, 100, and 20 Amol/L) parenthesis are for hRRM2. The model is based on an X-ray crystal structure of a murine R2 (PDB code 1W69) and was built with SYBYL were tried based on previous reports on other HCTs 6.9.2 (Tripos, Inc., St. Louis, MO). hRRM2 and p53R2 share 95.5 and (22, 23); 100 Amol/L Triapine was found to be the best dose 81.2% sequence identity with murine R2. B, structure of Triapine. C, UV- for UV-visible absorption detection. visible absorption spectra of Triapin, Fe(II)-(3-AP), and Fe(III)-(3-AP) in 50 mmol/L Tris-HCl buffer (pH 7.2) containing 100 mmol/L KCl. The Protein Expression concentrations are 100 Amol/L Triapine, 1% DMSO, 50 Amol/L FeCl3, hRRM2, p53R2, and hRRM1 were expressed using the and 5 mmol/L DTT. pET28-BL21(DE3) prokaryotic system and isolated to above 90% purity by immobilized-metal (Ni2+) affinity chroma- tography. Proteins were dialyzed against 50 mmol/L Tris- agents (16, 17). Clinical trials suggest that Triapine is a HCl buffer (pH 7.4) containing 100 mmol/L KCl and stored promising cancer chemotherapeutic drug. However, ad- at À70jC (3). verse effects that include methemoglobinemia and hypoxia In vitro Assays have been reported (18, 19). The enzymatic activity of recombinant ribonucleotide The mechanism of ribonucleotide reductase inhibition reductase was measured using a previously reported by Triapine, the function of iron, and the correlation [3H]CDP reduction method (3, 4). Briefly, 100 ALof between the pharmacologic and side effects of the drug reaction mixture contained 0.125 Amol/L [3H]CDP (24 remain unclear. We report an investigation of the Ci/mmol), 50 mmol/L HEPES (pH 7.2), 6 mmol/L DTT, inhibitory effects of free Triapine and when bound to 4 mmol/L MgOAc, 2 mmol/L ATP, 0.05 mmol/L CDP, ferric and ferrous ions on recombinant human ribonucle- 100 mmol/L KCl, and 0.25 Amol/L ribonucleotide otide reductases by in vitro activity assays, antioxidant reductase (5 Ag of hRRM1 and 2.5 Ag of hRRM2 or protection analysis, and electron paramagnetic resonance p53R2). The molar amount of holoenzyme was calculated (EPR) spectroscopy. Our spin-trapping experiments show using the molecular weight of the tetramer. Where that Fe(II)-(3-AP) reacts with dioxygen to give reactive indicated, up to 60 Amol/L FeCl3 was added. Samples oxygen species (ROS). We found that the species Fe(II)- were analyzed by high-performance liquid chromatogra- (3-AP) is a much more potent inhibitor than free Triapine phy and liquid scintillation counting after incubation at and Fe(III)-(3-AP). Cell proliferation assays indicate that 37jC for 30 minutes and dephosphorylation. The specific the redox-active Triapine-Fe complex plays a role in enzymatic activity was 79.2 F 2.82 nmol of dCDP Mol Cancer Ther 2006;5(3).
Load more

Recommended publications
  • Nitroxide-Mediated Polymerization
    Chapter 7 Nitroxide-Mediated Polymerization 7.1 Introduction Controlled radical polymerization (CRP) under radical initiation conditions belongs to priority areas in the development of the synthetic chemistry of polymers of the last years [1–16]. Nitroxide-mediated polymerization (NMP) was invented by Solomon [1, 13]. Since this discovery, nitroxide-mediated radical polymerization is a power- ful method to synthesize well-defined macromolecular architectures with precisely controlled topologies, compositions, microstructures, and functionalities [3–5]. The most common mechanisms for reversible activation in polymerization reactions are schematically illustrated in Scheme 7.1. Persistent radical effect (PRE) occurs when two radicals are generated at the same time, at the same rate, and one is more persistent than the other, the self-termination reactions are lowered, leading to an unusually high selectivity for the cross-coupling reaction [10]. The effect has been investigated for the preparation of macromolecules with a narrow molar mass distribution through radical polymerization. Nitroxide-mediated polymerization is widely applied in industrial polymer syn- theses as a method for production of large-tonnage polymers and is employed to manufacture new pigments, sealants, emulsion stabilizers, and block copolymers, etc., with a various set of properties. NMP has also paved an avenue for complex macromolecular architectures (statistical, block, graft) in the fields of nanoscience and nanotechnology [5, 9, 12] and references cited therein. A brief summary of NMP developments in both the patent and open literature during the period of the early Scheme 7.1 Mechanisms for reversible activation in polymerization reactions [6] © Springer Nature Switzerland AG 2020 161 G. I. Likhtenshtein, Nitroxides, Springer Series in Materials Science 292, https://doi.org/10.1007/978-3-030-34822-9_7 162 7 Nitroxide-Mediated Polymerization 1980–2000 was presented in [11].
    [Show full text]
  • Ribonucleotide Reductase Subunit M2B Deficiency Leads To
    Am J Transl Res 2018;10(11):3635-3649 www.ajtr.org /ISSN:1943-8141/AJTR0084684 Original Article Ribonucleotide reductase subunit M2B deficiency leads to mitochondrial permeability transition pore opening and is associated with aggressive clinicopathologic manifestations of breast cancer Lijun Xue1*, Xiyong Liu2,6*, Qinchuan Wang3,4, Charlie Q Liu3, Yunru Chen3, Wei Jia5, Ronhong Hsie6, Yifan Chen8, Frank Luh2,6, Shu Zheng7, Yun Yen2,6,8 1Department of Pathology, Loma Linda University Medical Center, Loma Linda, CA 92354, USA; 2Sino-American Cancer Foundation, California Cancer Institute, Temple, CA 91780, USA; 3Department of Molecular Pharmacology, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA; 4Surgical Oncology, Sir Runrun Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China; 5Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA; 6TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan, ROC; 7Cancer Institute, Zhejiang University, Hangzhou 310009, Zhejiang, China; 8PhD Program of Cancer Biology and Drug Discovery, Taipei Medical University, Taipei, Taiwan, ROC. *Co-first authors. Received August 27, 2018; Accepted October 19, 2018; Epub November 15, 2018; Published November 30, 2018 Abstract: Ribonucleotide reductase small subunit M2B (RRM2B) plays an essential role in maintaining mitochon- drial homeostasis. Mitochondrial permeability transition pore (MPTP) is a key regulator of mitochondrial homeo- stasis. MPTP contributes to cell death and is crucial in cancer progression. RRM2B’s relation to MPTP is not well known, and the role of RRM2B in cancer progression is controversial. Here, our aim was to study the role of RRM2B in regulating MPTP and the association between RRM2B and clinicopathological manifestations in breast cancer.
    [Show full text]
  • Mitochondrial Hepatopathies Etiology and Genetics the Hepatocyte Mitochondrion Can Function Both As a Cause and As a Target of Liver Injury
    Mitochondrial Hepatopathies Etiology and Genetics The hepatocyte mitochondrion can function both as a cause and as a target of liver injury. Most mitochondrial hepatopathies involve defects in the mitochondrial respiratory chain enzyme complexes (Figure 1). Resultant dysfunction of mitochondria yields deficient oxidative phosphorylation (OXPHOS), increased generation of reactive oxygen species (ROS), accumulation of hepatocyte lipid, impairment of other metabolic pathways and activation of both apoptotic and necrotic pathways of cellular death. Figure 1: Since the mitochondria are under dual control of nuclear DNA and mitochondrial DNA (mtDNA), mutations in genes of both classes have been associated with inherited mitochondrial myopathies, encephalopathies, and hepatopathies. Autosomal nuclear gene defects affect a variety of mitochondrial processes such as protein assembly, mtDNA synthesis and replication (e.g., deoxyguanosine kinase [dGUOK]) and DNA polymerase gamma [POLG]), and transport of nucleotides or metals. MPV17 (function unknown) and RRM2B (encoding the cytosolic p53-inducible ribonucleotide reductase small subunit) are two genes recently identified as also causing mtDNA depletion syndrome and liver failure, as has TWINKLE, TRMU, and SUCLG1. Most children with mitochondrial hepatopathies have identified or presumed mutations in these nuclear genes, rather than mtDNA genes. A classification of primary mitochondrial hepatopathies involving energy metabolism is presented in Table 1. Drug interference with mtDNA replication is now recognized as a cause of acquired mtDNA depletion that can result in liver failure, lactic acidosis, and myopathy in human immunodeficiency virus infected patients and, previously, in hepatitis B virus patients treated with nucleoside reverse transcriptase inhibitors. Current estimates suggest a minimum prevalence of all mitochondrial diseases of 11.5 cases per 100,000 individuals, or 1 in 8500 of the general population.
    [Show full text]
  • Arsenic Hexoxide Has Differential Effects on Cell Proliferation And
    www.nature.com/scientificreports OPEN Arsenic hexoxide has diferential efects on cell proliferation and genome‑wide gene expression in human primary mammary epithelial and MCF7 cells Donguk Kim1,7, Na Yeon Park2,7, Keunsoo Kang3, Stuart K. Calderwood4, Dong‑Hyung Cho2, Ill Ju Bae5* & Heeyoun Bunch1,6* Arsenic is reportedly a biphasic inorganic compound for its toxicity and anticancer efects in humans. Recent studies have shown that certain arsenic compounds including arsenic hexoxide (AS4O6; hereafter, AS6) induce programmed cell death and cell cycle arrest in human cancer cells and murine cancer models. However, the mechanisms by which AS6 suppresses cancer cells are incompletely understood. In this study, we report the mechanisms of AS6 through transcriptome analyses. In particular, the cytotoxicity and global gene expression regulation by AS6 were compared in human normal and cancer breast epithelial cells. Using RNA‑sequencing and bioinformatics analyses, diferentially expressed genes in signifcantly afected biological pathways in these cell types were validated by real‑time quantitative polymerase chain reaction and immunoblotting assays. Our data show markedly diferential efects of AS6 on cytotoxicity and gene expression in human mammary epithelial normal cells (HUMEC) and Michigan Cancer Foundation 7 (MCF7), a human mammary epithelial cancer cell line. AS6 selectively arrests cell growth and induces cell death in MCF7 cells without afecting the growth of HUMEC in a dose‑dependent manner. AS6 alters the transcription of a large number of genes in MCF7 cells, but much fewer genes in HUMEC. Importantly, we found that the cell proliferation, cell cycle, and DNA repair pathways are signifcantly suppressed whereas cellular stress response and apoptotic pathways increase in AS6‑treated MCF7 cells.
    [Show full text]
  • TRACE: Tennessee Research and Creative Exchange
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 8-2009 Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae James Wesley Fairman University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Biochemistry, Biophysics, and Structural Biology Commons Recommended Citation Fairman, James Wesley, "Structure-Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae. " PhD diss., University of Tennessee, 2009. https://trace.tennessee.edu/utk_graddiss/49 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by James Wesley Fairman entitled "Structure- Function Studies of the Large Subunit of Ribonucleotide Reductase from Homo sapiens and Saccharomyces cerevisiae." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the equirr ements for the degree of Doctor of Philosophy, with a major in Biochemistry and Cellular and Molecular Biology. Chris G. Dealwis,
    [Show full text]
  • RRM2B-Related Mitochondrial DNA Depletion Syndrome, Encephalomyopathic Form with Renal Tubulopathy
    RRM2B-related mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy Description RRM2B-related mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy (RRM2B-MDS) is a severe condition that begins in infancy and affects multiple body systems. It is associated with brain dysfunction combined with muscle weakness (encephalomyopathy). Many affected individuals also have a kidney dysfunction known as renal tubulopathy. Infants with RRM2B-MDS have weak muscle tone (hypotonia) and a failure to grow or gain weight at the expected rate (failure to thrive). Many have a smaller-than-normal head size (microcephaly). Due to muscle weakness, affected infants typically have difficulty controlling head movement and may have delayed development of other motor skills, such as rolling over or sitting. Weakness of the muscles used for breathing leads to serious breathing difficulties and can result in life-threatening respiratory failure. Most affected infants have a buildup of a chemical called lactic acid in the body (lactic acidosis), which can also be life-threatening. Some individuals with RRM2B-MDS have a digestion problem known as gastrointestinal dysmotility, in which the muscles and nerves of the digestive system do not move food through the digestive tract efficiently. This disorder may lead to swallowing difficulties, vomiting, and diarrhea and can contribute to a failure to thrive. Less commonly, individuals with RRM2B-MDS develop seizures or hearing loss that is caused by nerve damage in the inner ear (sensorineural hearing loss). Because of the severity of the signs and symptoms, people with RRM2B-MDS usually live only into early childhood. Frequency RRM2B-MDS is a rare condition; the exact prevalence is unknown.
    [Show full text]
  • Genomic Evidence of Reactive Oxygen Species Elevation in Papillary Thyroid Carcinoma with Hashimoto Thyroiditis
    Endocrine Journal 2015, 62 (10), 857-877 Original Genomic evidence of reactive oxygen species elevation in papillary thyroid carcinoma with Hashimoto thyroiditis Jin Wook Yi1), 2), Ji Yeon Park1), Ji-Youn Sung1), 3), Sang Hyuk Kwak1), 4), Jihan Yu1), 5), Ji Hyun Chang1), 6), Jo-Heon Kim1), 7), Sang Yun Ha1), 8), Eun Kyung Paik1), 9), Woo Seung Lee1), Su-Jin Kim2), Kyu Eun Lee2)* and Ju Han Kim1)* 1) Division of Biomedical Informatics, Seoul National University College of Medicine, Seoul, Korea 2) Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Korea 3) Department of Pathology, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea 4) Kwak Clinic, Okcheon-gun, Chungbuk, Korea 5) Department of Internal Medicine, Uijeongbu St. Mary’s Hospital, Uijeongbu, Korea 6) Department of Radiation Oncology, Seoul St. Mary’s Hospital, Seoul, Korea 7) Department of Pathology, Chonnam National University Hospital, Kwang-Ju, Korea 8) Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 9) Department of Radiation Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul, Korea Abstract. Elevated levels of reactive oxygen species (ROS) have been proposed as a risk factor for the development of papillary thyroid carcinoma (PTC) in patients with Hashimoto thyroiditis (HT). However, it has yet to be proven that the total levels of ROS are sufficiently increased to contribute to carcinogenesis. We hypothesized that if the ROS levels were increased in HT, ROS-related genes would also be differently expressed in PTC with HT. To find differentially expressed genes (DEGs) we analyzed data from the Cancer Genomic Atlas, gene expression data from RNA sequencing: 33 from normal thyroid tissue, 232 from PTC without HT, and 60 from PTC with HT.
    [Show full text]
  • Ribonucleotide Reductase: In-Vitro S- Glutathionylation of R2 and P53r2 Subunits of Mammalian Class I Ribonucleotide Reductase Protein
    Ribonucleotide Reductase: In-vitro S- glutathionylation of R2 and p53R2 Subunits of Mammalian Class I Ribonucleotide Reductase Protein Ajanta Chatterji Amity University Kolkata Arne Holmgren Karolinska Institutet RAJIB SENGUPTA ( [email protected] ) Amity University https://orcid.org/0000-0002-9665-8784 Short Report Keywords: Ribonucleotide reductases (RNR), S-glutathionylation, DNA, antiviral drugs Posted Date: August 24th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-823076/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Ribonucleotide reductases (RNR) catalyze the rate-limiting step in DNA synthesis during the S-phase of the cell cycle. Its constant activity in order to maintain dNTP homeostasis is a fascinating area of research and an attractive candidate for cancer research and antiviral drugs. Redox modication such as S-glutathionylation of the R1 subunit of mammalian RNR protein has been presumed to regulate the activity of RNR during catalytic cycles. Herein, we report S-glutathionylation of the R2 subunit. We have also shown Grx1 system can eciently deglutathionylate the S-glutathionylated R2 subunit. Additionally, our data also showed for the very rst time S-glutathionylation of mammalian p53R2 subunit that regulates DNA synthesis outside S-phase during DNA damage and repair. Taken together, these data will open new avenues for future research relating to exact physiological signicance, target thiols, and/or overall RNR activity due to S-glutathionylation of R2 and p53R2 subunits and provide valuable insights for effective treatment regimes. 1. Introduction: Ribonucleotide reductase (RNR) is an essential enzyme that catalyzes the rate-limiting step in the conversion of ribonucleotides (rNTP) to concomitant deoxyribonucleotides (dNTP) during de novo DNA synthesis [1, 2].
    [Show full text]
  • Screen for Abnormal Mitochondrial Phenotypes in Mouse Embryonic Stem Cells Identifies a Model for Succinyl-Coa Ligase Deficiency and Mtdna Depletion Taraka R
    © 2014. Published by The Company of Biologists Ltd | Disease Models & Mechanisms (2014) 7, 271-280 doi:10.1242/dmm.013466 RESOURCE ARTICLE Screen for abnormal mitochondrial phenotypes in mouse embryonic stem cells identifies a model for succinyl-CoA ligase deficiency and mtDNA depletion Taraka R. Donti1,‡, Carmen Stromberger1,*,‡, Ming Ge1, Karen W. Eldin2, William J. Craigen1,3 and Brett H. Graham1,§ ABSTRACT prevalence of mitochondrial disorders might be as high as 1 in 5000, Mutations in subunits of succinyl-CoA synthetase/ligase (SCS), a making mitochondrial disease one of the more common genetic component of the citric acid cycle, are associated with mitochondrial causes of encephalomyopathies and multisystem disease (Schaefer et encephalomyopathy, elevation of methylmalonic acid (MMA), and al., 2004; Elliott et al., 2008; Schaefer et al., 2008). Despite important mitochondrial DNA (mtDNA) depletion. A FACS-based retroviral- insights into clinical, biochemical and molecular features of these mediated gene trap mutagenesis screen in mouse embryonic stem disorders, the underlying molecular pathogenesis remains poorly (ES) cells for abnormal mitochondrial phenotypes identified a gene understood and no clearly effective therapies exist. Mitochondria trap allele of Sucla2 (Sucla2SAβgeo), which was used to generate contain their own genome that consists of a multicopy, ~16.4-kilobase transgenic mice. Sucla2 encodes the ADP-specific β-subunit isoform circular chromosome. This mitochondrial DNA (mtDNA) encodes 13 of SCS. Sucla2SAβgeo homozygotes exhibited recessive lethality, with polypeptides that are subunits of various respiratory chain complexes most mutants dying late in gestation (e18.5). Mutant placenta and as well as 22 tRNAs and two rRNAs required for mitochondrial embryonic (e17.5) brain, heart and muscle showed varying degrees protein translation.
    [Show full text]
  • Nucleotide Biosynthesis Links Glutathione Metabolism to Ferroptosis Sensitivity
    bioRxiv preprint doi: https://doi.org/10.1101/2021.07.14.452394; this version posted July 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Nucleotide Biosynthesis Links Glutathione Metabolism to Ferroptosis Sensitivity Amy Tarangelo1,3, Joon Tae Kim2, Jonathan Z. Long2, Scott J. Dixon1,4 1Department of Biology, Stanford University, 327 Campus Drive, Stanford, CA 94305, USA 2Department of Pathology and Stanford ChEM-H, Stanford University School of Medicine 291 Campus Drive, Stanford, CA 94305, USA 3Current address: Children’s Medical Center Research Institute, UT Southwestern, 6000 Harry Hines Blvd, Dallas, TX 75235 4Contact: [email protected] Key words: Cell death, iron, p53, p21 Running title: Nucleotide metabolism and ferroptosis bioRxiv preprint doi: https://doi.org/10.1101/2021.07.14.452394; this version posted July 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Abstract Nucleotide synthesis is a metabolically demanding process essential for cell division. Several anti-cancer drugs that inhibit nucleotide metabolism induce apoptosis. How inhibition of nucleotide metabolism impacts non-apoptotic cell death is less clear. Here, we report that inhibition of nucleotide metabolism by the p53 pathway is sufficient to suppress the non-apoptotic cell death process of ferroptosis.
    [Show full text]
  • Yeast to Study Human Purine Metabolism Diseases Bertrand Daignan-Fornier, Benoit Pinson
    Yeast to Study Human Purine Metabolism Diseases Bertrand Daignan-Fornier, Benoit Pinson To cite this version: Bertrand Daignan-Fornier, Benoit Pinson. Yeast to Study Human Purine Metabolism Diseases. Cells, MDPI, 2019, 8 (1), pp.67. 10.3390/cells8010067. hal-02346566 HAL Id: hal-02346566 https://hal.archives-ouvertes.fr/hal-02346566 Submitted on 5 Nov 2019 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. cells Review Yeast to Study Human Purine Metabolism Diseases Bertrand Daignan-Fornier 1,2,* and Benoît Pinson 1,2 1 Université de Bordeaux IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France; [email protected] 2 Centre National de la Recherche Scientifique IBGC UMR 5095 1, rue Camille Saint-Saëns, F-33077 Bordeaux, France * Correspondence: [email protected]; Tel.: +33-556-999-001; Fax: +33-556-999-059 Received: 8 January 2019; Accepted: 15 January 2019; Published: 17 January 2019 Abstract: Purine nucleotides are involved in a multitude of cellular processes, and the dysfunction of purine metabolism has drastic physiological and pathological consequences. Accordingly, several genetic disorders associated with defective purine metabolism have been reported.
    [Show full text]
  • Knockdown of Hnrnpa0, a Del(5Q) Gene, Alters Myeloid Cell Fate In
    Myelodysplastic Syndromes SUPPLEMENTARY APPENDIX Knockdown of Hnrnpa0 , a del(5q) gene, alters myeloid cell fate in murine cells through regulation of AU-rich transcripts David J. Young, 1 Angela Stoddart, 2 Joy Nakitandwe, 3 Shann-Ching Chen, 3 Zhijian Qian, 4 James R. Downing, 3 and Michelle M. Le Beau 2 1Department of Pediatrics, Division of Oncology, Johns Hopkins University, Baltimora, MD; 2Department of Medicine and the Compre - hensive Cancer Center, University of Chicago, IL; 3St. Jude Children's Research Hospital, Memphis, Tennessee; and 4University of Illi - nois Cancer Center, Chicago, IL, USA DJY and AS equally contributed to this work. ©2014 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2013.098657 Manuscript received on September 25, 2013. Manuscript accepted on February 13, 2014. Correspondence: [email protected] Supplementary Materials for D. Young et al. Purification of hematopoietic populations from mice. Cells from the spleens, thymi, and bone marrow of C57BL/6J mice were harvested as appropriate for each population. For primitive populations including Lin–Sca-1+Kit+ (LSK), common lymphoid (CLP) and myeloid (CMP) progenitors, and granulocyte- monocyte progenitors (GMP), the cells were depleted of mature cells using the Mouse Hematopoietic Progenitor Cell Enrichment Kit (StemCell Technologies). The cells were stained for appropriate lineage markers, as described in Supplementary Figure S1, and sorted using a FACSAria fluorescence activated cell sorter (BD Biosciences). Real-time RT-PCR analysis Total RNA was purified from cells using Stat-60 (Tel-Test), according to the manufacturer’s protocols. First-strand cDNA was synthesized using SuperScript III SuperMix for qRT-PCR (Invitrogen) containing both random hexamers and oligo(dT)20 for priming.
    [Show full text]